Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFALL: Ramucirumab + Cisplatin + Capecitabine as First-line Therapy in Metastatic Gastric or GEJ Adenocarcinoma
jRCT2080222775Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and Esophago-Gastric Adenocarcinoma comparing Ramucirumab + Cisplatin + Capecitabine with Placebo + Cisplatin + Capecitabine (2 arms).
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222775.